- Advertisement -
NEW YORK–(BUSINESS WIRE)–Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance…
Click here to view the original article.
